USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AuraSense Therapeutics LLC
Address:
8045 Lamon Avenue
Suite 410
Skokie, IL
EIN:
452638444
DUNS:
968721535
Number of Employees:
16
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $149,295.00 1
SBIR Phase II $986,621.00 1

Award List:

Genetically Programmable Spherical Nucleic Acids as Rapidly Adaptable Nanotherapeutics

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$149,295.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
David Giljohann, Chief Scientific Officer – (847) 467-2887
Abstract:
AuraSense Therapeutics is developing oligonucleotide-modified gold nanoparticles called spherical nucleic acid (SNA) constructs, which are a powerful new way of regulating cellular gene expression. AuraSense Therapeutics will use SNAs as genetically programmable antimicrobial agents in a manner to… More

Genetically Programmable Spherical Nucleic Acids as Rapidly Adaptable Nanotherapeutics

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$986,621.00
Agency / Branch:
DOD / DARPA
Principal Investigator:
David Giljohann, COO – (847) 673-1702
Abstract:
AuraSense Therapeutics is developing oligonucleotide-modified gold nanoparticles called Spherical Nucleic Acid (SNA) constructs, which are a powerful new way of regulating cellular gene expression. AuraSense Therapeutics will use SNAs as genetically programmable antimicrobial agents in a manner to… More